Role of Hyperbaric Oxygen Therapy in Prostate Tumor Microenvironment and Cancer Stem Cell Niche DOI Creative Commons

Pranathi Konda,

Merrel Holley,

Viswanathan Lakshmanan

et al.

annals of urologic oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 15, 2024

Hyperbaric oxygen therapy (HBOT), has gained attention in recent years as a potential adjunct to conventional cancer treatments, particularly addressing tumor hypoxia which is extensively employed post-injury treatment, the administration of >92% at 1.5- 3.0 ATA for 60-120 minutes. HBOT attributed least five mechanisms including epigenetic regulation gene expression, mechanical effects, bacteriostatic hyperoxygenation carbon monoxide and cyanide poisoning restoration from hypoxia. emerging promising overcoming hypoxia—a key feature microenvironment (TME) that drives growth, resistance, metastasis. By delivering high concentrations under pressure, improves tissue oxygenation, potentially suppressing reducing hypoxia-induced enhancing efficacy chemotherapy radiotherapy. Studies have shown its anti-angiogenic effects some models ability alkalize TME. In prostate cancer, demonstrated slowing growth increasing treatment sensitivity cell lines like DU-145 LNCaP. Additionally, it may enhance effectiveness radical prostatectomy by synchronizing cycles. Therefore, current review highlights aspects their role late radiation injury (LRTI) We succinctly captured multifaceted modifying TME comprehensive overview focuses on advanced approaches eliminate stem cells (PCSCs) exploration anti-androgen well stemness-related signaling pathways growing body evidence supporting benefits treatment. Further clinical research could lead significant advancements

Language: Английский

Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance DOI Creative Commons
Zhipeng Wang, Jie Wang,

Dengxiong Li

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101232 - 101232

Published: Feb. 1, 2025

Language: Английский

Citations

1
IDO/Kynurenine; novel insight for treatment of inflammatory diseases DOI
Naser‐Aldin Lashgari, Nazanin Momeni Roudsari, Maryam Shayan

et al.

Cytokine, Journal Year: 2023, Volume and Issue: 166, P. 156206 - 156206

Published: April 28, 2023

Language: Английский

Citations

23
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment DOI Creative Commons

Duocai Li,

Weidong Xu,

Yifan Chang

et al.

Acta Biochimica et Biophysica Sinica, Journal Year: 2023, Volume and Issue: 55(6), P. 956 - 973

Published: May 10, 2023

The distinct tumor microenvironment (TME) of prostate cancer (PCa), which promotes proliferation and progression, consists various stromal cells, immune a dense extracellular matrix (ECM). understanding the TME extends to tertiary lymphoid structures (TLSs) metastasis niches provide more concise comprehension metastasis. These constituents collectively structure hallmarks pro-tumor TME, including immunosuppressive, acidic, hypoxic niches, neuronal innervation, metabolic rewiring. In combination with knowledge advancement emerging therapeutic technologies, several strategies have been developed, some them tested in clinical trials. This review elaborates on PCa components, summarizes TME-targeted therapies, provides insights into carcinogenesis, strategies.

Language: Английский

Citations

18
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables DOI Creative Commons
Andrea Palicelli, Martina Bonacini, Stefania Croci

et al.

Cells, Journal Year: 2021, Volume and Issue: 10(11), P. 3166 - 3166

Published: Nov. 14, 2021

Immunotherapy targeting the PD-1-PD-L1 axis yielded good results in treating different immunologically ''hot'' tumors. A phase II study revealed therapeutic activity of pembrolizumab selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes immunohistochemical expression PD-L1 human PC samples and highlights pre-analytical interpretation variables. Interestingly, 29% acinar PCs, 7% ductal 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria applied variable specimen-types, evaluating tumors showing clinic-pathologic features. The positivity rate antibody clones tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding single case tested for RM-320. most clone was E1L3N, followed by 22C3 (most used eligibility), SP263, SP142, 28-8, gave rates 35%, 11-41% (depending systems), 6%, 3%, 15%, respectively. Other <200 cases. usually higher than benign tissues. It non-tissue microarray specimens (41-50% vs. 15%), as frequently showed heterogenous focal PD-L1-staining. expressed immune stromal 12% 69% cases, Tumor heterogeneity, inter-institutional preanalytics, inter-observer variability may account result biases.

Language: Английский

Citations

28
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes DOI Creative Commons
Andrea Palicelli, Stefania Croci, Alessandra Bisagni

et al.

Biomedicines, Journal Year: 2022, Volume and Issue: 10(2), P. 236 - 236

Published: Jan. 22, 2022

Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR).

Language: Английский

Citations

20
Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics DOI Creative Commons

Xionghui He,

Xiang Chen, Changcheng Yang

et al.

PeerJ, Journal Year: 2024, Volume and Issue: 12, P. e16951 - e16951

Published: Feb. 29, 2024

Gastric cancer (GC) is a malignant tumor that originates from the epithelium of gastric mucosa and has poor prognosis. Stomach adenocarcinoma (STAD) covers 95% total cancer. This study aimed to identify prognostic value RNA methylation-related genes in In this study, The Cancer Genome Atlas (TCGA)-STAD GSE84426 cohorts were downloaded public databases. Patients classified by consistent cluster analysis based on prognosis-related differentially expressed methylation Prognostic obtained differential expression, univariate Cox least absolute shrinkage selection operator (LASSO) analyses. model was established validated training set, test set validation respectively. Independent implemented. Finally, expression affirmed reverse transcription quantitative PCR (RT-qPCR). total, four (ACTA2, SAPCD2, PDK4 APOD) related identified enrolled into risk signature. STAD patients divided high- low-risk groups medium score, high-risk group had addition, methylation-relevant signature sets, authenticated as reliable independent predictor. nomogram constructed predictors predict 1/3/5-year survival probability patients. gene enrichment (GSEA) result suggested prognosis subgroup may be immune-related pathways. experimental results indicated trends cells agreement with bioinformatics. Our novel for STAD, which considerable significance improving offering theoretical support clinical therapy.

Language: Английский

Citations

4
Advances in the Immunomodulatory Properties of Glycoantigens in Cancer DOI Open Access
Valeria da Costa, Teresa Freire

Cancers, Journal Year: 2022, Volume and Issue: 14(8), P. 1854 - 1854

Published: April 7, 2022

Aberrant glycosylation in tumour progression is currently a topic of main interest. Tumour-associated carbohydrate antigens (TACAs) are expressed wide variety epithelial cancers, being both diagnostic tool and potential treatment target, as they have impact on patient outcome disease progression. Glycans affect tumour-cell biology properties well the antitumor immune response. It has been ascertained that TACAs cell migration, invasion metastatic when by cancer cells or their extracellular vesicles. On other hand, tumour-associated glycans recognized C-type lectin receptors possess immunomodulatory which enable growth response evasion. Yet, much remains unknown, concerning mechanisms involved deregulation glycan synthesis how this affects major level. This review summarises findings to date aberrant influence immunity, application spotlights unanswered challenges remaining be solved.

Language: Английский

Citations

18
Machine learning analysis identified NNMT as a potential therapeutic target for hepatocellular carcinoma based on PCD-related genes DOI Creative Commons

Fuqun Wei,

P.C. Huang, Bing Zhang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 3, 2025

Language: Английский

Citations

0
PD-L1 expression in prostate cancer and Gleason Grade Group: is there any relationship? Findings from a multi-institutional cohort. DOI Creative Commons
Vincenzo Fiorentino,

Ludovica Pepe,

Cristina Pizzimenti

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155916 - 155916

Published: March 1, 2025

Language: Английский

Citations

0
Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and PD-1/PD-L1 Pathway Inhibition DOI Open Access
Ming-Yen Tsai,

Chung-Kuang Lu,

Li‐Hsin Shu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2684 - 2684

Published: March 17, 2025

Prostate cancer remains a significant global health challenge, necessitating the development of novel therapeutic approaches. This study investigated potential Antrodia cinnamomea formula (XIANZHIFANG formula, XZF), comprising cinnamomea, Sanghuangporus sanghuang, Ganoderma lucidum, sinense, and Inonotus obliquus, in prostate treatment. HPLC analysis confirmed presence key triterpenoids, including Antcin A, B, C, K, Zhankuic acid 4,7-dimethoxy-5-methyl-1,3-benzodioxole. Cytotoxicity assays demonstrated that XZF (50–200 μg/mL) exhibited selective activity, maintaining viability non-cancerous 293T-cells while enhancing activated CD8+ CD4+ T-cells dose-dependent manner. significantly reduced PD-1 expression but not inhibited PD-L1/PD-1 interaction, achieving 93% inhibition at 200 μg/mL. Furthermore, when combined with atezolizumab (1 μg/mL), complete blockade interaction. In cells, differential antiproliferative effects. PC-3 across concentration range 25–200 μg/mL, whereas DU145 cells showed only partial higher concentrations (100–200 μg/mL). LNCaP reduction viability, mirroring response pattern cells. Conditioned medium from XZF-treated macrophages, particularly human THP-1 suppressed migration Notably, conditioned stronger inhibitory effect on cell compared to murine RAW 264.7 macrophages. These findings indicate exerts its through multiple mechanisms, direct effects enhancement T-cell responses, modulation immune checkpoint pathways, macrophage-mediated suppression survival migration. The pronounced observed macrophage models suggest promising avenue for further investigation clinical settings, combination existing immunotherapies.

Language: Английский

Citations

0